Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Ovid Therapeutics Inc (OVID)

Ovid Therapeutics Inc (OVID)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 111,803
  • Shares Outstanding, K 71,212
  • Annual Sales, $ 570 K
  • Annual Income, $ -26,430 K
  • EBIT $ -41 M
  • EBITDA $ -40 M
  • 60-Month Beta 0.22
  • Price/Sales 16.88
  • Price/Cash Flow N/A
  • Price/Book 2.53

Options Overview Details

View History
  • Implied Volatility 135.09% (-20.72%)
  • Historical Volatility 88.21%
  • IV Percentile 8%
  • IV Rank 4.92%
  • IV High 1,303.49% on 06/17/25
  • IV Low 74.69% on 09/08/25
  • Expected Move (DTE 33) 0.4250 (27.07%)
  • Put/Call Vol Ratio 0.25
  • Today's Volume 327
  • Volume Avg (30-Day) 324
  • Put/Call OI Ratio 0.07
  • Today's Open Interest 11,331
  • Open Int (30-Day) 11,685
  • Expected Range 1.1450 to 1.9950

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.10
  • Number of Estimates 9
  • High Estimate -0.06
  • Low Estimate -0.17
  • Prior Year -0.13
  • Growth Rate Est. (year over year) +23.08%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.2600 +24.60%
on 12/18/25
1.8800 -16.49%
on 12/24/25
+0.0200 (+1.29%)
since 12/16/25
3-Month
1.1800 +33.05%
on 11/14/25
1.8800 -16.49%
on 12/24/25
unch (unch)
since 10/16/25
52-Week
0.2425 +547.42%
on 04/09/25
2.0100 -21.89%
on 10/03/25
+0.8400 (+115.07%)
since 01/16/25

Most Recent Stories

More News
Ovid Therapeutics Reports Phase 1 Results for the First-Ever Direct Activator of Potassium-Chloride Cotransporter 2 (KCC2), OV350 Intravenous (IV)

OV350 showed a good safety profile, supporting the advancement of the Company’s KCC2 portfolio, including the first oral direct activator, OV4071 There were no treatment-related laboratory findings,...

OVID : 1.5700 (-1.26%)
Ovid Therapeutics Appoints Dr. Petra Kaufmann as Chief Medical Officer

NEW YORK, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company developing small molecule medicines for brain disorders with significant unmet need, today...

OVID : 1.5700 (-1.26%)
Ovid Therapeutics Announces Planned Leadership Succession and Reports Business Updates and Third Quarter 2025 Financial Results

Meg Alexander appointed Chief Executive Officer effective January 1, 2026; Dr. Jeremy M. Levin to transition to Executive Chair of the Board of Directors Next-generation GABA-aminotransferase (GABA-AT)...

OVID : 1.5700 (-1.26%)
B. Riley Securities Sticks to Their Buy Rating for Ovid Therapeutics (OVID)

B. Riley Securities analyst Madison Elsaadi maintained a Buy rating on Ovid Therapeutics today and set a price target of $5.00. The company’s shares closed today at $1.74.Elevate Your Investing Strategy:...

OVID : 1.5700 (-1.26%)
Oppenheimer upgrades Ovid Therapeutics (OVID) to a Buy

In a report released today, Jay Olson from Oppenheimer upgraded Ovid Therapeutics to a Buy, with a price target of $7.00. The company’s shares closed yesterday at $1.58.Elevate Your Investing Strategy:...

OVID : 1.5700 (-1.26%)
Wedbush Sticks to Its Buy Rating for Ovid Therapeutics (OVID)

Wedbush analyst Laura Chico maintained a Buy rating on Ovid Therapeutics today and set a price target of $5.00. The company’s shares closed today at $1.84.Elevate Your Investing Strategy: Take advantage...

OVID : 1.5700 (-1.26%)
Ovid Therapeutics Secures $175.1M in Private Placement

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Ovid Therapeutics...

OVID : 1.5700 (-1.26%)
William Blair Sticks to Its Buy Rating for Ovid Therapeutics (OVID)

In a report released today, Myles Minter from William Blair maintained a Buy rating on Ovid Therapeutics. The company’s shares opened today at $2.00.Elevate Your Investing Strategy: Take advantage of...

OVID : 1.5700 (-1.26%)
Ovid Therapeutics Announces Pricing of Private Placement Totaling up to $175 Million in Gross Proceeds

NEW YORK, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to developing small molecule medicines for brain conditions with significant unmet...

OVID : 1.5700 (-1.26%)
Ovid announces positive topline results for the next-generation GABA-aminotransferase inhibitor, OV329, that demonstrate strong inhibitory activity and a potential best-in-category safety profile

An expansive biomarker study confirmed OV329 delivered statistically significant inhibition of GABA-AT as measured across multiple metrics OV329 matched or exceeded inhibition demonstrated by therapeutic...

OVID : 1.5700 (-1.26%)

Business Summary

Ovid Therapeutics Inc. is a biopharmaceutical company. It engaged in developing therapies for patients with rare neurological disorders. The company's product pipeline consists of OV101, is currently in development for the treatment of symptoms of Angelman syndrome and Fragile X syndrome. It also involved...

See More

Key Turning Points

3rd Resistance Point 1.6867
2nd Resistance Point 1.6633
1st Resistance Point 1.6167
Last Price 1.5700
1st Support Level 1.5467
2nd Support Level 1.5233
3rd Support Level 1.4767

See More

52-Week High 2.0100
Last Price 1.5700
Fibonacci 61.8% 1.3348
Fibonacci 50% 1.1263
Fibonacci 38.2% 0.9177
52-Week Low 0.2425

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar